Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Maintains Rejection on Claims in Benitec's US Patent


Benitec said last week that the US Patent and Trademark Office has again rejected certain claims within the company's core US patent, although other claims that had previously been rejected were deemed allowable.

The patent, No. 6,573,099, covers gene-expression knockdown using DNA that transcribes double-stranded RNA, and has long been the centerpiece of the company’s intellectual property estate.

The IP fell under USPTO scrutiny as part of a protracted patent-infringement battle Benitec waged with now-defunct expressed RNAi shop Nucleonics (see RNAi News, 4/2/2004).

Previously, the patent office rejected the patent’s claims based on objections related to the fundamental Fire and Mello patent held by the Carnegie Institute.

Benitec appealed the ruling, and said last week that certain of the '099 patent's claims were deemed free of prior art and allowable. However, "other claims remain rejected as obvious prior art," primarily in light of the Fire patent, the company said.

"It is the view of Benitec … that this represents progress in the re-examination, albeit slow," Benitec noted, adding that a reply to the USPTO's latest finding will be submitted no later than March 7.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.